Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data
Alimentary Pharmacology and Therapeutics, 07/14/09
Hughes D et al. - The model suggests acceptable ICERs for biological agents when considering a lifetime horizon with periods of up to 4 years continuous therapy. As with all economic evaluations, the results may not be generalizable beyond the perspective of analysis.
Related Articles
A Case-Control Study on Risk Factors of Osteoporosis in Patients with Crohn's Disease
Archives of Iranian Medicine, 11/13/09
Relevance Score: 69%
Impact of disease activity on resting energy expenditure in children with inflammatory bowel disease
Clinical Nutrition, 11/18/09
Relevance Score: 68%
Gastrointestinal stromal tumor causing small bowel intussusception in a patient with Crohn's disease
World Journal of Gastroenterology, 11/13/09
Relevance Score: 68%
Pathogenesis of inflammatory bowel disease (IBD)
The Internet Journal of Gastroenterology, 11/13/09
Relevance Score: 68%
Methotrexate for maintenance of remission in Crohn's disease
Cochrane Reviews, 10/27/09
Relevance Score: 68%
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin
Current Medical Research and Opinion, 12/11/09
Economic consequences of ACS-related rehospitalizations in the US
Current Medical Research and Opinion, 12/10/09
Out-of-pocket Prices of Opioid Analgesics in the United States, 1999–2004
Pain Medicine, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor